Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;59(2):72-75.
doi: 10.1053/j.seminhematol.2022.02.002. Epub 2022 Feb 8.

Epidemiology of VITT

Menaka Pai  1
Affiliations

Epidemiology of VITT

Menaka Pai. Semin Hematol. 2022 Apr.

Abstract

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a life-threatening syndrome of aggressive thrombosis, often profound thrombocytopenia, and frequently overt disseminated intravascular coagulation. It has been associated with 2 adenovirus vector COVID-19 vaccines: ChAdOx1 nCoV-19 (AstraZeneca) and Ad26.COV2.S (Janssen). Unlike the myriad of other conditions that cause thrombosis and thrombocytopenia, VITT has an important distinguishing feature: affected individuals have platelet activating anti-PF4 antibodies that appear in a predictable time frame following vaccination. The reported incidence of VITT differs between jurisdictions; it is dependent on accurate ascertainment of cases and accurate estimates of the size of the vaccinated population. The incidence ranges from 1 case per 26,500 to 127,3000 first doses of ChAdOx1 nCoV-19 administered. It is estimated at 1 case per 518,181 second doses of ChAdOx1 nCoV-19 administered, and 1 case per 263,000 Ad26.COV2.S doses administered. There are no clear risk factors for VITT, including sex, age, or comorbidities. VITT is a rare event, but its considerable morbidity and mortality merit ongoing pharmacovigilance, and accurate case ascertainment.

Keywords: COVID-19; Epidemiology; Thrombocytopenia; Thrombosis; Vaccine.

PubMed Disclaimer

References

    1. Warkentin TE, Pai M. VIPIT versus VITT: what's in a name? Thromb Res. 2021;207:158–160. - PubMed
    1. Michalik S, Siegerist F, Palankar R, et al. Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines. Haematologica. 2022 - PMC - PubMed
    1. Pishko AM, Cuker A. Thrombosis after vaccination with messenger RNA-1273: is this vaccine-induced thrombosis and thrombocytopenia or thrombosis with thrombocytopenia syndrome? Ann Intern Med. 2021;174(10):1468–1469. - PMC - PubMed
    1. Sangli S, Virani A, Cheronis N, et al. Thrombosis with thrombocytopenia after the messenger RNA-1273 vaccine. Ann Intern Med. 2021;174(10):1480–1482. - PMC - PubMed
    1. Case series of thrombosis with thrombocytopenia syndrome following COVID-19 vaccination—United States, December 2020–August 2021 | medRxiv [Internet]. [cited 2022 Jan 29]. Available from: https://www.medrxiv.org/content/10.1101/2021.11.10.21266063v1. - DOI - PMC - PubMed

MeSH terms